More physiologically and pathologically relevant preclinical human liver models are needed for drug liver liability assessment and liver disease modeling. While Drug-Induced Liver Injury (DILI) remains a major safety concern, several recent high-profile NAFLD/NASH clinical trial failures further highlight this critically unmet need. With the advances in 3D culture, we and others have demonstrated the […]

- Home
- News
- DDW Exclusive Content
- Opinion
- Business
- Regulatory
- Intelligence
Categories
Latest Industry Intelligence
- Cancer Research
- Webinars
- Podcasts
- Archive
- Videos